Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Other Non-Current Liabilities (2020 - 2025)

Cytek Biosciences' Other Non-Current Liabilities history spans 6 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 2.41% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 2.41%, while the annual FY2025 figure was $2.3 million, 2.41% down from the prior year.
  • Other Non-Current Liabilities reached $2.3 million in Q4 2025 per CTKB's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $2.5 million in Q3 2025 to a low of $737000.0 in Q3 2021.
  • Average Other Non-Current Liabilities over 5 years is $1.8 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: skyrocketed 94.98% in 2022, then dropped 12.13% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.2 million in 2021, then skyrocketed by 31.81% to $1.6 million in 2022, then soared by 53.18% to $2.4 million in 2023, then decreased by 2.76% to $2.4 million in 2024, then fell by 2.41% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Other Non-Current Liabilities are $2.3 million (Q4 2025), $2.5 million (Q3 2025), and $2.5 million (Q2 2025).